SCHEMBL225262

SCHEMBL225262

O=C1C(c2ccccc2)CN1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
TSHR P16473 2/20 0.46
ROCK2 O75116 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
DDB1 Q16531 2/20 0.43
CRBN Q96SW2 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 2/20 0.42
ALDH1A1 P00352 2/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.41
FADS1 O60427 1/20 0.41
ALOX15 P16050 1/20 0.41
GRM2 Q14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL2910884 0.98 KMT2A (0.45) KMT2AMEN1NPC1RAB9ATSHR
SCHEMBL6964905 0.88 FADS1 (0.50) KMT2AMEN1TSHRROCK2ALDH1A1
SCHEMBL8495437 0.84 ATM (0.51) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL8495439 0.84 ATM (0.51) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL4721528 0.81 ROCK2 (0.62) KMT2AMEN1NPC1RAB9ATSHR
SCHEMBL9309143 0.78 ROCK2 (0.52) KMT2AMEN1NPC1RAB9ATSHR
SCHEMBL7758080 0.78 ROCK2 (0.36) KMT2AMEN1NPC1RAB9ATSHR
SCHEMBL1958248 0.77 ROCK2 (0.51) KMT2AMEN1NPC1RAB9ATSHR
SCHEMBL7436193 0.74 ALDH1A1 (0.45) KMT2AMEN1NPC1RAB9ATSHR
SCHEMBL3289329 0.73 KMT2A (0.47) KMT2AMEN1TSHRSMN1; SMN2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4712959-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF Mirum Pharmaceuticals, Inc. (US) 2026-03-25 EP claimed
WO-2024243023-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF MIRUM PHARMACEUTICALS, INC. (US) 2024-11-28 WO claimed
US-8207146-B2 Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical SANOFI-AVENTIS (FR) 2012-06-26 US claimed
EP-2203448-B1 PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL SANOFI AVENTIS (FR) 2011-06-22 EP claimed
US-7956085-B2 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-06-07 US claimed
US-20100261643-A1 PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL SANOFI-AVENTIS (FR) 2010-10-14 US claimed
US-20100035961-A1 Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-02-11 US claimed
CN-100582092-C Process for preparing diphenyl azetidinone derivatives AVENTIS PHARMA GMBH 2010-01-20 CN claimed
CN-101535326-A Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof SANOFI AVENTIS DEUTSCHLAND (DE) 2009-09-16 CN claimed
US-7563888-B2 Process for the preparation of diphenyl azetidinone derivatives SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-21 US claimed
US-20070149501-A1 PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-28 US claimed
CN-1956951-A Method for producing diphenyl azetidinone derivatives AVENTIS PHARMA GMBH (DE) 2007-05-02 CN claimed
CN-1805926-A Process for the preparation of trans-isomers of diphenylazetidinone derivatives RANBAXY LAB LTD (IN) 2006-07-19 CN claimed
EP-1626954-A2 PROCESS FOR THE PREPARATION OF TRANS-ISOMERS OF DIPHENYLAZETIDINONE DERIVATIVES RANBAXY LABORATORIES, LTD. (IN) 2006-02-22 EP claimed
WO-2004099132-A2 PROCESS FOR THE PREPARATION OF TRANS-ISOMERS OF DIPHENYLAZETIDINONE DERIVATIVES RANBAXY LABORATORIES LIMITED (IN) 2004-11-18 WO claimed
EP-4712959-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF Mirum Pharmaceuticals, Inc. (US) 2026-03-25 EP disclosed
WO-2024243023-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF MIRUM PHARMACEUTICALS, INC. (US) 2024-11-28 WO disclosed
WO-2002050068-A1 DIPHENYL AZETIDINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-06-27 WO disclosed
US-20020013501-A1 Process for the preparation of hydroxy and amino compounds CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2002-01-31 US disclosed
EP-1167325-A1 Process for preparing hydroxy and amino compounds Consortium für elektrochemische Industrie GmbH (DE) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149501-A1 PROCESS FOR THE PREPARATION OF DIPHENYL AZETIDINONE DERIVATIVES CYP46A1, APOB, DHCR7 KMT2A 1869/4885MEN1 1200/4885NPC1 22/4885
US-20100261643-A1 PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL QDPR, DYRK4, CLK4 KMT2A 1077/4885MEN1 2839/4885NPC1 2308/4885
US-20100035961-A1 Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof BBOX1, CYP2E1, CYP3A4 KMT2A 2699/4885MEN1 615/4885NPC1 482/4885
US-20020013501-A1 Process for the preparation of hydroxy and amino compounds BCKDK, KHK, HRH1 KMT2A 645/4885MEN1 1379/4885NPC1 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.